Stocks · News reference
Pfizer announced 18% year-over-year revenue growth for the second quarter, excluding currency effects, and increased its full-year revenue forecast midpoint by $500 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs. For
Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
Pfizer reported strong Q3 results, beating analyst expectations with $16.6B in revenue (vs. $15.9B forecast) and $0.87 EPS (vs. $0.73 expected). The company raised full-year guidance and highlighted 32% growth from launched and acquired products. Trading at a modest 10x forward P/E with a 5.6% dividend yield, the stock may be positioned for further gains despite being down 30% over five years due to declining COVID-related revenues.
Filed: 2026-11-03 AccNo: 0000078003-26-000125 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Pfizer Inc. announced its financial results for the third quarter of 2026 and increased its full-year 2026 revenue and adjusted diluted EPS guidance.
Pfizer Inc. has appointed Cecile Guegan as its permanent Chief Financial Officer and Executive Vice President, effective November 1, 2026.